Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Dcvc Bio
BioCentury | Feb 13, 2025
Finance
Newleos launches with $93.5M, neuropsychiatry candidates from Roche: Venture Report
Plus: DeepMind veterans raise $50M for AI-guided protein design start-up; crossovers back Abcuro’s pivotal study; and more
BioCentury | Jan 14, 2025
Finance
How VCs at the AI-bio interface set up their portfolios for success
Some firms are playing an active role in overcoming data starvation and bolstering the infrastructure ecosystem
BioCentury | Jan 10, 2025
Finance
Life science VCs driving AI innovation: the view from the interface in 2025
How VC firms focused on AI-driven drug development think about the resources and strategies needed to turn promise into reality
BioCentury | Dec 12, 2024
Deals
Nvelop, Chroma merger creates opportunity for targeted epigenome editors
Nvelop CEO Jeff Walsh will lead nChroma, which has $75M in new funding and a lead for HBV
BioCentury | Aug 9, 2024
Finance
Venture Report: Pair of crossover rounds for precision oncology, peptide biotechs
Plus: Financings for newcos Nilo, Jade, Red Queen
BioCentury | May 8, 2024
Emerging Company Profile
Avicenna: Using machine learning to skip the hit-to-lead phase
Seeded by DCVC Bio, Avicenna’s machine learning tech is designed to find a clinical candidate in a haystack of theoretical compounds
BioCentury | May 2, 2024
Finance
Venture report: Rounds for psychedelic play Reunion, cancer company Delphia
Plus: Syndicate backs BridgeBio’s cancer spinout, AbCellera teams with investors to form asset-focused newcos, and more
BioCentury | Dec 16, 2023
Management Tracks
Mistras, Martin join Viatris
Plus: Nassim Usman at the helm at Totus as it raises $66M series B round, and updates from Tourmaline, HKEX, CIRM, CorMedix and RiverVest
BioCentury | Aug 2, 2023
Emerging Company Profile
Solu’s CyTaCs bring antibody pharmacology to small molecule targets
With tech from GSK and a $31 million seed round, the company aims to enter the clinic within two years
BioCentury | Aug 1, 2023
Finance
Aug. 1 Quick Takes: Ex-U.S. deal for TG’s Briumvi comes as sales disappoint
Plus: ATP extends Aulos’ series A, Solu debuts with platform from GSK, and more
Items per page:
1 - 10 of 39